PDGFRA and gastrointestinal stromal tumor: Advanced GISTs including unresectable, recurrent or metastatic are initially managed by imatinib; however, GIST patients may have primary resistance to imatinib due to mutations in KIT or PDGFRA rendering the patients less responsive to imatinib.